SequelSEC

Onconetix, Inc. ONCO

Pharmaceutical Preparations · CIK 0001782107 · Fiscal year ends 1231

Revenue
$815.37K
Fiscal year ended 2025-12-31
Operating income
-$17.86M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Onconetix, Inc. (ONCO) reported revenue of $815.37K and net income of -$14.03M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Onconetix, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Onconetix, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Revenue$815.37K$2.52M$58.46K
Cost of revenue$182.46K$1.47M$1.19M
Gross profit$632.91K$1.06M-$1.13M
Operating income-$17.86M-$56.49M-$36.03M
Net income-$14.03M-$58.69M-$37.41M
Research & developmentUnavailable$154.36K$1.95M
Weighted-average diluted sharesUnavailableUnavailableUnavailable
Pretax income-$14.03M-$59.74M-$37.42M
Income tax expense$525-$1.05M-$12.59K
Diluted EPS$-16.56$-1,823.39$-87.45
Selling, general & administrative$7.04M$11.23M$14.77M
General & administrativeUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailable

Balance

Onconetix, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalentsUnavailableUnavailableUnavailable
Total assets$24.93M$28.18M$87.52M
Current assets$6.07M$950.27K$5.84M
Total liabilities$9.16M$18.57M$21.88M
Current liabilities$9.14M$18.29M$17.19M
Total equity incl. NCI$15.76M$8.54M$1.40M
Temporary (mezzanine) equityUnavailableUnavailable$64.24M
Inventory$149.96K$64.08K$364.05K
Accounts receivable$296.87K$25.72K$149.73K
Goodwill$18.55M$27.05M$55.68M
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$1.76M$3.79M$5.30M

Cash flow

Onconetix, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$9.68M-$10.50M-$13.58M
Capital expendituresUnavailable$28.47K$3.30K
Investing cash flowUnavailable-$28.47K-$8.65M
Financing cash flow$14.45M$6.74M$1.04M
Net change in cash$4.57M-$3.91M-$21.20M
Stock-based compensation$74.27K$438.65K$329.76K
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortization$15.17K$731.34K$43.94K

Derived

Onconetix, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flowUnavailable-$10.52M-$13.58M
Gross margin77.6%41.8%-1927.9%
Operating margin-2190.0%-2238.0%-61634.5%
FCF marginUnavailable-416.9%-23235.0%
SBC / revenue9.1%17.4%564.0%
Current ratio0.66x0.05x0.34x
Revenue YoY growth-67.7%4217.3%Unavailable
Net margin-1721.0%-2325.2%-63986.5%
R&D / revenueUnavailableUnavailable3334.3%
CapEx / revenueUnavailable1.1%5.6%
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ONCO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-06-12View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2024-12-31

Difference 1067928 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.